Scarica l'app Stockscreener
22.50
0.92%
-0.21
Dopo l'orario di chiusura:
22.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNDM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$22.71
Aprire:
$22.71
Volume 24 ore:
1.21M
Relative Volume:
0.64
Capitalizzazione di mercato:
$1.53B
Reddito:
$796.00M
Utile/perdita netta:
$-136.49M
Rapporto P/E:
-10.77
EPS:
-2.09
Flusso di cassa netto:
$-64.24M
1 W Prestazione:
+2.37%
1M Prestazione:
+8.49%
6M Prestazione:
+35.38%
1 anno Prestazione:
-39.98%
Intervallo 1D:
$22.06
$23.35
Intervallo di 1 settimana:
$21.35
$23.95
Portata 52W:
$9.98
$37.93
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Nome
Tandem Diabetes Care Inc
Settore
Industria
Telefono
858-366-6900
Indirizzo
12400 HIGH BLUFF DRIVE, San Diego, CA
Confronta TNDM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
22.50 | 1.54B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
126.18 | 220.91B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.38 | 146.24B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.21 | 140.64B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.69 | 127.91B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.58 | 49.23B | 5.88B | 1.34B | 799.60M | 2.3489 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-10-21 | Ripresa | Stifel | Hold |
| 2025-09-08 | Iniziato | Oppenheimer | Outperform |
| 2025-08-12 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Downgrade | Citigroup | Neutral → Sell |
| 2025-06-16 | Iniziato | Truist | Hold |
| 2025-04-10 | Iniziato | Mizuho | Neutral |
| 2025-03-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-10-04 | Iniziato | Goldman | Neutral |
| 2024-10-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Aggiornamento | Stifel | Hold → Buy |
| 2023-08-04 | Downgrade | Citigroup | Buy → Neutral |
| 2023-05-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-15 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-08-09 | Downgrade | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Underweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Iniziato | Wells Fargo | Overweight |
| 2020-07-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-18 | Reiterato | Raymond James | Outperform |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-06 | Iniziato | Raymond James | Outperform |
| 2020-02-04 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Iniziato | Guggenheim | Buy |
| 2019-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2019-05-17 | Reiterato | BofA/Merrill | Neutral |
| 2019-05-13 | Iniziato | SVB Leerink | Outperform |
| 2019-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2019-03-05 | Reiterato | BofA/Merrill | Neutral |
| 2019-02-27 | Reiterato | Lake Street | Buy |
| 2018-11-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Reiterato | Dougherty & Company | Buy |
| 2018-09-26 | Reiterato | Piper Jaffray | Overweight |
Mostra tutto
Tandem Diabetes Care Inc Borsa (TNDM) Ultime notizie
Will Tandem Diabetes Care Inc. stock gain from strong economyQuarterly Earnings Summary & Consistent Profit Trading Strategies - ulpravda.ru
Will Tandem Diabetes Care Inc. stock benefit from green energy trends2025 Top Gainers & Community Supported Trade Ideas - ulpravda.ru
Will Tandem Diabetes Care Inc. stock outperform value stocksJuly 2025 Update & Weekly Breakout Stock Alerts - ulpravda.ru
Tandem Diabetes and Roche Reach a Patent Settlement - MSN
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Yahoo Finance
How interest rate cuts could boost Tandem Diabetes Care Inc. stockJuly 2025 Patterns & Daily Entry Point Alerts - ulpravda.ru
How resilient is Tandem Diabetes Care Inc. stock in market downturnsGap Down & Weekly Sector Rotation Insights - ulpravda.ru
Published on: 2026-01-08 20:49:56 - ulpravda.ru
Published on: 2026-01-08 20:49:15 - ulpravda.ru
Is Tandem Diabetes Care Inc. (TD5A) stock supported by free cash flowQuarterly Trade Summary & AI Enhanced Execution Alerts - ulpravda.ru
Tandem Diabetes Care (TNDM) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures - MSN
What risks investors should watch in Tandem Diabetes Care Inc. stockEconomic Indicators Overview & Budget Friendly Portfolio Growth - ulpravda.ru
Will Tandem Diabetes Care Inc. stock benefit from infrastructure spendingFlag and Pennant Patterns & Low Cost Capital Trading - ulpravda.ru
Why Tandem Diabetes Care Inc. (TD5A) stock is a strong analyst pick2026 world cup usa national team qualification defensive leaders pressing system knockout prediction breakdown - ulpravda.ru
Positive changes ahead for diabetes in 2026 - BioWorld MedTech
Reasons to hold Tandem Diabetes stock in your portfolio for now - MSN
Tandem Diabetes Care (FRA:TD5A) EV-to-OCF : -178.93 (As of Jan. 03, 2026) - GuruFocus
The End of Shots? 5 Biotech Stocks Rethinking Diabetes - The Globe and Mail
Disposable Insulin Pumps Market is expected to reach US$ 6.9 - openPR.com
Tandem Diabetes Care, Inc. (TNDM) Stock Analysis: Assessing Future Growth in the Medical Devices Sector - DirectorsTalk Interviews
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors t - GuruFocus
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - PR Newswire
Tandem Diabetes Care Updates Bylaws, Tightens Governance Rules - TipRanks
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - ACCESS Newswire
Favourable Signals For Tandem Diabetes Care: Numerous Insiders Acquired Stock - 富途牛牛
ROSEN, LEADING INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE - GlobeNewswire Inc.
HEDIS Glycemic Goal Achieved Using Control-IQ Technology - The American Journal of Managed Care® (AJMC®)
Is Tandem Diabetes Care (TNDM) Still Undervalued After Its Recent Share Price Rebound? - Yahoo Finance
What Tandem Diabetes Care (TNDM)'s Canadian Smartphone Bolus Launch Means For Shareholders - Yahoo Finance
Tandem Diabetes Care (FRA:TD5A) EV-to-OCF : -179.84 (As of Dec. 25, 2025) - GuruFocus
Should Tandem’s Canadian Smartphone Bolus Launch Reshape How Investors View TNDM’s Connected-Care Strategy? - Sahm
Insulin Delivery Devices Market Outlook: Market to Reach US$ - openPR.com
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - ACCESS Newswire
Artificial Pancreas System Market is set for steady growth to US$ - openPR.com
Price-Driven Insight from (TNDM) for Rule-Based Strategy - news.stocktradersdaily.com
Clinical ink announces collaboration with Tandem Diabetes Care to integrate Automated Insulin Delivery data into the GlucoseReady™ connected device software platform - PRWeb
ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - ACCESS Newswire
Gainers Report: Why Tandem Diabetes Care Inc. (TD5A) stock could break out in 2025Trade Risk Assessment & Verified Momentum Stock Watchlist - Улправда
Will Tandem Diabetes Care Inc. (TD5A) stock beat value stocksJuly 2025 Snapshot & Fast Gain Stock Trading Tips - Улправда
Taking Stock of Tandem Diabetes Care (TNDM) After t:slim App Launch and Rising Growth Optimism - Sahm
TNDM Investor News: If You Have Suffered Losses in Tandem - GlobeNewswire
Book value per share of Tandem Diabetes Care, Inc. – SWB:TD5A - TradingView — Track All Markets
Stock Analysis: Will Tandem Diabetes Care Inc. stock split again soonWeekly Trading Summary & Free Expert Verified Stock Movement Alerts - Улправда
Is Tandem Diabetes Care Inc. stock oversold or undervaluedMarket Performance Recap & Community Verified Trade Signals - DonanımHaber
Q3 2025 Healthcare Technology Earnings Review: Revenue Beats & Stock PerformanceNews and Statistics - IndexBox
Will Tandem Diabetes Care Inc. stock deliver better than expected guidanceWeekly Investment Recap & Community Driven Trade Alerts - ulpravda.ru
Unpacking Q3 Earnings: Tandem Diabetes (NASDAQ:TNDM) In The Context Of Other Healthcare Technology Stocks - Yahoo Finance
What makes Tandem Diabetes Care Inc. (TD5A) stock appealing to growth investorsWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - ulpravda.ru
TNDM Sees Analyst Rating Maintain and Price Target Rise by Truis - GuruFocus
Truist Securities Adjusts Price Target on Tandem Diabetes Care to $24 From $17, Maintains Hold Rating - marketscreener.com
Tandem t:slim Mobile App Now Available in Canada - Business Wire
Tandem Diabetes Care Inc Azioni (TNDM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.10%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):